Literature DB >> 6138080

Pharmacokinetics and bioavailability of midazolam in man.

P Heizmann, M Eckert, W H Ziegler.   

Abstract

The pharmacokinetic behaviour and the bioavailability of midazolam were investigated in six volunteers after intravenous (0.15 mg/kg) and oral administration (10, 20 and 40 mg). Following rapid intravenous injection of midazolam, the plasma concentration of the substance decreased to approximately 10% within 2 h owing to a rapid rate of distribution. A two compartment model adequately described the kinetics of midazolam in plasma. The following average values were found: elimination half-life, 2.3 h; total clearance, 323 ml/min, and apparent volume of distribution at steady-state (VSS), 50.21. After oral administration, the drug is rapidly absorbed. Maximum plasma levels are reached within 30 min and the drug is rapidly eliminated from plasma with practically the same half-life as determined after i.v. administration. The bioavailability after the ingestion of 10, 20 and 40 mg midazolam in the form of tablets ranged from 31 to 72%, due to the high liver extraction quota of midazolam.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138080      PMCID: PMC1428091          DOI: 10.1111/j.1365-2125.1983.tb02270.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Determination of water soluble imidazo-1,4-benzodiazepines in blood by electron- capture gas--liquid chromatography and in urine by differential pulse polaragraphy.

Authors:  C V Puglisi; J C Meyer; L D'Arconte; A Brooks; J A de Silva
Journal:  J Chromatogr       Date:  1978-01-01

2.  Automated gas chromatography for studies of midazolam pharmacokinetics.

Authors:  D J Greenblatt; A Locniskar; H R Ochs; P M Lauven
Journal:  Anesthesiology       Date:  1981-08       Impact factor: 7.892

3.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

4.  Excretion and metabolism of 14C-midazolam in humans following oral dosing.

Authors:  P Heizmann; W H Ziegler
Journal:  Arzneimittelforschung       Date:  1981
  4 in total
  76 in total

1.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

Authors:  P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

2.  Pregnane X receptor-mediated induction of Cyp3a by black cohosh.

Authors:  Xiaoyan Pang; Jie Cheng; Kristopher W Krausz; De-an Guo; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2010-10-27       Impact factor: 1.908

3.  Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.

Authors:  J W Mandema; E Tukker; M Danhof
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

4.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

5.  A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Authors:  Pierre-Eric Juif; Margaux Boehler; Yves Donazzolo; Shirin Bruderer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

6.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

7.  The pharmacokinetics of midazolam in patients with congestive heart failure.

Authors:  I H Patel; P P Soni; E K Fukuda; D F Smith; C V Leier; H Boudoulas
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  The pharmacokinetics of midazolam following orthotopic liver transplantation.

Authors:  M P Shelly; J S Dixon; G R Park
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

9.  Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.

Authors:  Vibeke Andersen; Natalie Pedersen; Niels-Erik Larsen; Jesper Sonne; Steen Larsen
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

10.  4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

Authors:  Caroline Gjestad; Duy Khanh Huynh; Tore Haslemo; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.